Townsend Raymond 4

Accession 0001250853-21-000087

CIK 0001561743other

View on SEC.gov Company Profile

Filed

Aug 29, 8:00 PM ET

Accepted

Aug 30, 3:45 PM ET

Size

27.5 KB

Accession

0001250853-21-000087

Insider Transaction Report

Form 4

Period: 2021-08-27

Kindred Biosciences, Inc.KIN

Townsend Raymond

Director

Transactions

Disposition to Issuer
Common Stock
2021-08-27$9.25/sh−24,928$230,584→ 0 total
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$2.29/sh−44,000$100,760→ 0 total
Exercise: $6.96Exp: 2025-01-26→ Common Stock (44,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$4.81/sh−50,000$240,500→ 0 total
Exercise: $4.44Exp: 2031-01-19→ Common Stock (50,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$2.25/sh−20,000$45,000→ 0 total
Exercise: $7.00Exp: 2023-12-11→ Common Stock (20,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27−34,000→ 0 total
Exercise: $15.41Exp: 2024-02-03→ Common Stock (34,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$5.80/sh−18,892$109,574→ 0 total
Exercise: $3.45Exp: 2026-01-08→ Common Stock (18,892 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$2.85/sh−49,900$142,215→ 0 total
Exercise: $6.40Exp: 2027-01-23→ Common Stock (49,900 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27$0.50/sh−75,000$37,500→ 0 total
Exercise: $8.75Exp: 2028-01-22→ Common Stock (75,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27−50,000→ 0 total
Exercise: $9.91Exp: 2029-01-31→ Common Stock (50,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-08-27−50,000→ 0 total
Exercise: $9.84Exp: 2030-01-16→ Common Stock (50,000 underlying)

Footnotes (10)

[F1]Represents 24,928 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share.
[F10]This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $240,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F2]This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of December 11, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued service as director on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $45,000.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F3]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
[F4]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $100,760.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F5]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $109,573.60, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F6]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $142,215.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F7]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $37,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
[F8]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
[F9]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

Kindred Biosciences, Inc.

CIK 0001561743

→

Entity typeother

Related Parties

filerCIK 0001593867

Filing Metadata

Form type: 4
Filed: Aug 29, 8:00 PM ET
Accepted: Aug 30, 3:45 PM ET
Size: 27.5 KB

View on SEC.gov